SPONSOR
Dana-Farber Cancer Institute
Total Trials
15
Recruiting
15
Phases
EARLY_Phase 1, Phase 2, Phase 1
Conditions studied: Pancreas CancerLung CancerRenal CancerAdrenal MetastasesProstate CancerLiver MetastasesOligoprogressive Nodal MetastasesMetachronous Nodal MetastasesSynchronous Nodal MetastasesMesothelioma
Dana-Farber Cancer Institute is a clinical research sponsor with 15 registered studies on ClinicalTrials.gov, of which 15 are actively recruiting participants. Research covers conditions including Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases.
The trial portfolio spans EARLY_Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Dana-Farber Cancer Institute
How many clinical trials has Dana-Farber Cancer Institute sponsored?
ClinicalMetric currently tracks 15 clinical trials sponsored by Dana-Farber Cancer Institute, of which 15 are actively recruiting participants. These trials cover conditions including Pancreas Cancer, Lung Cancer, Renal Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Dana-Farber Cancer Institute research focus on?
Dana-Farber Cancer Institute clinical trials span Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, and additional conditions. The research pipeline includes EARLY_Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Dana-Farber Cancer Institute clinical trial?
To participate in a Dana-Farber Cancer Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Dana-Farber Cancer Institute trials with current recruitment status updated daily.
Clinical Trials by Dana-Farber Cancer Institute
NCT04115254
Recruiting
Stereotactic Magnetic Resonance Guided Radiation Therapy
Pancreas Cancer
NCT06664151 EARLY_Phase 1
Recruiting
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Skin Cancer
NCT04434040 Phase 2
Recruiting
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Breast Cancer
NCT06936878
Recruiting
BOLSTER: Learning New Skills to Thrive
Gastrointestinal Cancer
NCT07397611 Phase 2
Recruiting
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Renal Cell Carcinoma
NCT04188535
Recruiting
Serial MRI Scans During Radiation Therapy
Glioblastoma
NCT07232043
Recruiting
ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
Cancer
NCT05356117
Recruiting
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
Pancreatic Cancer
NCT06805617 Phase 2
Recruiting
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Salivary Gland Cancer
NCT05922761 Phase 2
Recruiting
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Bronchiolitis Obliterans Syndrome
NCT06321484 Phase 1
Recruiting
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Platinum-resistant Ovarian Cancer
NCT06945120
Recruiting
ACT Lung Health Intervention: Phase Two
Smoking Cessation
NCT07735624 Phase 2
Recruiting
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
Early Rectal Cancer
NCT06152809 Phase 1
Recruiting
CIML NK Cells With Venetoclax for AML
Acute Myeloid Leukemia
NCT05726370 Phase 2
Recruiting
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Head and Neck Squamous Cell Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology